Obesity drug safety tracked in Follow-Up study

NCT ID NCT07153172

Recruiting now Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up on people who previously took the experimental drug INV-347 for obesity. Researchers will monitor their health and measure how much of the drug remains in their blood over time. No new drug is given. The goal is to ensure the drug is safe in the long run.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INV-347
What this could lead to: If successful, this study will confirm that INV-347 is safe over the long term, supporting its further development as a potential obesity treatment.
What could go wrong: This is a small, early-phase follow-up study with no new treatment given. It only monitors safety and drug levels, so it cannot prove effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Syneos Health Clinique
RECRUITING

Québec, G1P 0A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.